Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1997 Sep;88(9):900–906. doi: 10.1111/j.1349-7006.1997.tb00467.x

Cytotoxicity of Trimetrexate against Antifolate‐resistant Human T‐Cell Leukemia Cell Lines Developed in Oxidized or Reduced Folate

Hayato Miyachi 1,✉, Yuzuru Takemura 2, Hiroyuki Kobayashi 2, Yasuhiko Ando 1
PMCID: PMC5921512  PMID: 9369939

Abstract

Cytotoxicity of trimetrexate (TMQ), a lipophilic dihydrofolate reductase inhibitor, was examined in antifolate‐resistant human T‐cell leukemia cell lines developed in oxidized or reduced folate. An approximately 60‐fold methotrexate (MTX)‐resistant subline was developed in oxidized folate (pter‐oylglutamic acid: PGA) (CCRF‐CEM/MTX60‐PGA) from human T‐cell leukemia cell line CCRF‐CEM; this line exhibited impaired membrane transport of the drug. Further enhancement of MTX resistance resulted in selection of an approximately 5000‐fold MTX‐resistant subline (CCRF‐CEM/ MTX5000‐PGA), which showed increased dihydrofolate reductase activity due to gene amplification in addition to further impairment of MTX transport. An approximately 140‐fold MTX‐resistant subline, and then a 1500‐fold MTX‐resistant subline were developed in reduced folate (10 nM leucovorin) (CCRF‐CEM/MTXm‐LV and CCRF‐CEM/MTX140‐LV); they exhibited increased dihydrofolate reductase due to gene amplification accompanied by increased intracellular drug accumulation of MTX. While CCRF‐CEM/MTX140‐LV and CCRF‐CEM/MTX1500‐LV cells showed cross‐resistance to TMQ, CCRF‐CEM/MTX60‐PGA and CCRF‐CEM/MTX5000‐PGA cells were at least as sensitive to TMQ as the parent cells. TMQ was more potent against approximately 200‐fold N10‐propargyl‐5,8‐dideazafolic‐acid (CB3717)‐resistant human T‐cell leukemia MOLT‐3 sublines developed in PGA (MOLT‐3/CB3717200‐PGA) or leucovorin (MOLT‐3/CB3717200‐LV), as compared to the parent cells; MOLT‐3/CB3717200‐PGA and MOLT‐3/CB3717200‐LV cells were resistant to CB3717 by virtue of impaired transport, only the former possessing gene amplification of thymidylate synthase. The Cytotoxicity of TMQ in both MOLT‐3/CB3717200‐PGA and MOLT‐3/CB3717200‐LV cells was reduced by addition of leucovorin in a dose‐dependent manner, suggesting intracellular folate deficiency as a cause of TMQ sensitivity. These results demonstrate that TMQ overcomes transport‐impaired antifolate resistance, irrespective of gene amplification of dihydrofolate reductase or thymidylate synthase. Types of folate used during the development of antifolate resistance seem to be important in relation to the mechanism of TMQ responsiveness as well as that of antifolate resistance.

Keywords: Trimetrexate, Methotrexate, Folate, Transport, Gene amplification

Full Text

The Full Text of this article is available as a PDF (461.4 KB).

REFERENCES

  • 1. ) Gorlick , R. , Goker , E. , Trippett , T. , Waltham , M. , Banerjee , D. and Bertino , J. R.Intrinsic and acquired resistance' to methotrexate in acute leukemia . N. Engl. J. Med. , 335 , 1041 – 1048 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Bertino , J. R. , Sawicki , W. L. , Moroson , B. A. , Cashmore , A. R. and Elslager , E. F.2,4‐Diamino‐5‐methyl‐6‐[(3,4,5‐trimethoxyanilino)methyl] quinazoline (TMQ), a potent non‐classical folate antagonist inhibitor‐I. Effect on di‐hydrofolate reductase and growth of rodent tumors in vitro and in vivo . Biochem. Pharmacol. , 28 , 1983 – 1987 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Kamen , B. A. , Eibl , B. , Cashmore , A. and Bertino , J. R , Uptake and efficacy of trimetrexate (TMQ, 2,4‐diamino‐5‐methyl‐6‐ [(3,4,5‐trimethoxyanilino) methyl] quinazoline), a non‐classical antifolate in methotrexate‐resistant leukemia cells in vitro . Biochem. Pharmacol. , 33 , 1697 – 1699 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Kano , Y. , Ohnuma , T. and Holland , J. F.Folate requirements of methotrexate‐resistant human acute lymphoblastic leukemia cell lines . Blood , 68 , 586 – 591 ( 1986. ). [PubMed] [Google Scholar]
  • 5. ) Ohnoshi , T. , Ohnuma , T. , Takahashi , I. , Scanlon , K. , Kamen , B. A. and Holland , J. F.Establishment of methotrexate‐resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists . Cancer Res. , 42 , 1655 – 1660 ( 1982. ). [PubMed] [Google Scholar]
  • 6. ) Pizzorno , G. , Mini , E. , Coronnello , M. , McGuire , J. J. , Moroson , B. A. , Cashmore , A. R. , Dreyer , R. N. , Lin , J. T. , Mazzei , T. , Periti , P. and Bertino , J. R.Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF‐CEM cells after short‐term, high‐dose treatment with this drug . Cancer Res. , 48 , 2149 – 2155 ( 1988. ). [PubMed] [Google Scholar]
  • 7. ) Miyachi , H. , Takemura , Y. , Ando , Y. and Scanlon , K. J.The role of folates in the development of methotrexate resistance in human leukemia cell line K562 . J. Cancer Res. Clin. Oncol. , 119 , 101 – 105 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Jackson , R. C. , Jackman , A. L. and Calvert , A. H.Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N‐(4‐(N‐ {2‐amino‐4‐hydroxy‐6‐quinazoli‐nyl)methyl} prop‐2‐ynylamino)benzoyl} ‐L‐glutamic acid (CB3717), on human lymphoblastoid cells . Biochem. Pharmacol. , 32 , 3783 – 3790 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Miyachi , H. , Takemura , Y. , Kobayashi , H. and Ando , Y.Amplification of the thymidylate synthase gene in an N10‐propargy1‐5,8‐dideazafolic‐acid‐resistant human leukemia, MOLT‐3 cell line developed in pteroylglutamic acid, but not in leucovorin . J. Cancer Res. Clin, Oncol , 122 , 659 – 664 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Miyachi , H. , Tiao , L. , Sowers , L. C. and Scanlon , K. J.Collateral sensitivity to azidothymidine in methotrexate resistant human leukemia cells . In Vivo , 6 , 7 – 22 ( 1992. ). [PubMed] [Google Scholar]
  • 11. ) Masters , J. N. , Yang , J. K. , Cellini , A. and Attardi , G.A human dihydrofolate reductase pseudogene and its relationship to the multiple forms of specific messenger RNA . J. Mol Biol , 167 , 23 – 36 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Bertino , J. R. , Perkins , J. P. and Johns , D. G.Purification and properties of dihydrofolate reductase from Ehrlich ascites carcinoma cells . Biochemistry , 4 , 839 – 846 ( 1965. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Ohnuma , T. and Kano , Y.Resistance of tumor cells to anticancer agents: resistance to methotrexate . Oncologia (Tokyo) , 5 , 95 – 108 ( 1983. ). [Google Scholar]
  • 14. ) Herbert , V. , Larrabee , A. R. and Buchanan , J. M.Studies on the identification of a folate compound of human serum . J. Clin. Invest. , 41 , 1134 – 1138 ( 1962. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Ohnuma , T. , Scanlon , K. J. , Kamen , B. A. , Ohnoshi , T. , Wolman , S. R. and Holland , J. F.Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro . Cancer Res. , 45 , 1815 – 1822 ( 1985. ). [PubMed] [Google Scholar]
  • 16. ) Alam , A. , Geddes , A. J. and North , A. C. T.Methods and mechanisms for the development of MTX resistance in human lymphoid cells . Int. J. Cancer , 31 , 45 – 50 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Mini , E. , Moroson , B. A. , Franco , C. T. and Bertino , J. R.Cytotoxic effects of folate antagonists against methotrexate‐resistant human leukemic lymphoblast CCRF‐CEM cell lines . Cancer Res. , 45 , 325 – 330 ( 1985. ). [PubMed] [Google Scholar]
  • 18. ) Diddens , H. , Niethammer , D. and Jackson , R. C.Patterns of cross‐resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate . Cancer Res. , 43 , 5286 – 5292 ( 1983. ). [PubMed] [Google Scholar]
  • 19. ) Sirotnak , F. M. , Moccio , D. M. , Goutas , L. J. , Kelleher , L. E. and Montgomery , J. A.Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate‐resistant murine tumors to the lipophilic antifolate, metoprine . Cancer Res. , 42 , 924 – 928 ( 1982. ). [PubMed] [Google Scholar]
  • 20. ) Takemura , Y. , Kobayashi , H. , Gibson , W. , Kimbell , R. , Miyachi , H. and Jackman , A. L.The influence of drug‐exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukemia cells . Int. J. Cancer , 66 , 29 – 36 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Rodenhuis , S. , McGuire , J. J. , Sawicki , W. L. and Bertino , J. R.Effects of methotrexate and of the “nonclassical” folate antagonist trimetrexate on human leukemia cells , Leukemia , 1 , 116 – 120 ( 1987. ). [PubMed] [Google Scholar]
  • 22. ) Takemura , Y. , Kobayashi , H. , Miyachi , H. , Gibson , W. , Kimbell , R. and Jackman , A. L.Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs . Jpn. J. Cancer Res. , 87 , 773 – 780 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES